Data from Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer

Abstract

<div>Abstract<p><b>Background:</b> While numerous susceptibility loci for epithelial ovarian cancer (EOC) have been identified, few associations have been reported with overall survival. In the absence of common prognostic genetic markers, we hypothesize that rare coding variants may be associated with overall EOC survival and assessed their contribution in two exome-based genotyping projects of the Ovarian Cancer Association Consortium (OCAC).</p><p><b>Methods:</b> The primary patient set (Set 1) included 14 independent EOC studies (4,293 patients) and 227,892 variants, and a secondary patient set (Set 2) included six additional EOC studies (1,744 patients) and 114,620 variants. Because power to detect rare variants individually is reduced, gene-level tests were conducted. Sets were analyzed separately at individual variants and by gene, and then combined with meta-analyses (73,203 variants and 13,163 genes overlapped).</p><p><b>Results:</b> No individual variant reached genome-wide statistical significance. A SNP previously implicated to be associated with EOC risk and, to a lesser extent, survival, rs8170, showed the strongest evidence of association with survival and similar effect size estimates across sets (<i>P</i><sub>meta</sub> = 1.1E−6, HR<sub>Set1</sub> = 1.17, HR<sub>Set2</sub> = 1.14). Rare variants in <i>ATG2B</i>, an autophagy gene important for apoptosis, were significantly associated with survival after multiple testing correction (<i>P</i><sub>meta</sub> = 1.1E−6; <i>P</i><sub>corrected</sub> = 0.01).</p><p><b>Conclusions:</b> Common variant rs8170 and rare variants in <i>ATG2B</i> may be associated with EOC overall survival, although further study is needed.</p><p><b>Impact:</b> This study represents the first exome-wide association study of EOC survival to include rare variant analyses, and suggests that complementary single variant and gene-level analyses in large studies are needed to identify rare variants that warrant follow-up study. <i>Cancer Epidemiol Biomarkers Prev; 25(3); 446–54. ©2016 AACR</i>.</p></div>